For individuals with dominantly inherited Alzheimer disease (DIAD), long-term treatment with gantenerumab may delay clinical decline.

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer's disease (DIAD). Gantenerumab was associated with ...

Early-onset Alzheimer’s disease progresses more rapidly and often strikes people in the prime of their lives. A new treatment ...

Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

"I am highly optimistic now, as this could be the first clinical evidence of what will become preventions for people at risk for Alzheimer's disease." HealthDay News — For individuals with ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ( Kisunla) have since received federal government approval and are being ...